Auris Medical (NASDAQ:EARS) – Auris Medical’s Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
- Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a main human nasal airway epithelium mannequin from its Bentrio (AM-301) nasal spray for COVID-19.
- AM-301 was discovered to be protected in vitro, and it considerably decelerated viral titer progress in experimental fashions of prophylaxis and mitigation.
- The manuscript of the preclinical data is available here.
- Prophylactic remedy with AM-301 was protecting towards SARS-CoV-2 an infection. The each day utility of the product beginning 10 minutes earlier than inoculation led to a 2-log (99%) discount in viral titer by Day 4 in comparison with controls.
- Inserts that acquired the product each day, beginning 24 or 30 hours after viral an infection, additionally had a decrease viral titer, equivalent to a 12- or 14-fold decrease TCID50 on the finish of the remedy.
- The time profile of SARS-CoV-2 an infection was considerably decelerated in comparison with controls each within the case of prophylactic remedy and within the case of mitigation remedy beginning 24 or 30 hours post-infection.
- Value Motion: EARS shares are up 1.61% at $3.22 through the market session on the final verify Wednesday.
© 2021 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
https://www.benzinga.com/basic/biotech/21/07/21977706/auris-medicals-bentrio-nasal-spray-shows-encouraging-preclinical-action-in-prevention-mitigation-?utm_source=feedburner&utm_medium=feed&utm_campaign=Feedpercent3A+benzinga+%28Benzinga+Information+Feedpercent29
